| Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer (NCT05447910) | Mayo Clinic | 2022-07-21 |
| Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer (NCT05183828) | University of Washington | 2022-01-23 |
| Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer (NCT04857697) | Mayo Clinic | 2021-07-01 |
| Study of the Safety of MRI Scans in People Who Have Breast Tissue Expanders After Mastectomy (NCT04769960) | Memorial Sloan Kettering Cancer Center | 2021-02-19 |
| Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer (NCT04535323) | Mayo Clinic | 2020-09-23 |
| RBX7455 Before Surgery for the Treatment of Operable Breast Cancer (NCT04139993) | Mayo Clinic | 2020-08-31 |
| Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer (NCT04517838) | Mayo Clinic | 2020-07-31 |
| Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients (NCT04300829) | Centre Leon Berard | 2020-06-06 |
| TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery (NCT04197687) | Academic and Community Cancer Research United | 2020-02-20 |
| Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib (NCT03094052) | University of California, San Francisco | 2018-10-09 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer (NCT03432741) | Mayo Clinic | 2018-03-27 |
| Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer (NCT03137693) | H. Lee Moffitt Cancer Center and Research Institute | 2017-11-29 |
| Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer (NCT03106415) | Mayo Clinic | 2017-09-27 |
| Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer (NCT03250676) | Eisai Inc. | 2017-08-23 |
| Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca (NCT02957968) | Virginia Commonwealth University | 2017-01-24 |
| Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer (NCT02824575) | Montefiore Medical Center | 2016-07-01 |
| Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (NCT02453620) | National Cancer Institute (NCI) | 2016-02-12 |
| Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer (NCT02530489) | M.D. Anderson Cancer Center | 2016-02-04 |
| Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer (NCT02488967) | NRG Oncology | 2015-07-26 |
| Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer (NCT02282345) | M.D. Anderson Cancer Center | 2015-04-16 |
| Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (NCT02115282) | National Cancer Institute (NCI) | 2014-03-29 |
| Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer (NCT02037529) | Academic and Community Cancer Research United | 2014-01-17 |
| Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas (NCT01942629) | Rambam Health Care Campus | 2013-10-01 |
| Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (NCT01730833) | City of Hope Medical Center | 2013-07-17 |
| PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer (NCT01697293) | Prescient Therapeutics, Ltd. | 2012-01-01 |
| Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer (NCT01245712) | M.D. Anderson Cancer Center | 2010-11-15 |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement (NCT00869206) | Alliance for Clinical Trials in Oncology | 2009-03-01 |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (NCT00433511) | National Cancer Institute (NCI) | 2007-11-02 |
| Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (NCT00310180) | National Cancer Institute (NCI) | 2006-04-07 |
| Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer (NCT00005970) | National Cancer Institute (NCI) | 2000-05-19 |